Nonetheless, ongoing development of ultra‐rapid insulin analogues and refinement of closed‐loop algorithms are warranted to further optimise glycaemic outcomes and reduce user burden in type 1 diabetes. Here, INS is linked to type 1 diabetes mellitus.